Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone914-347-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$471.43 million
Profitability
Miscellaneous
Employees474
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics Inc (NASDAQ:ACOR) announced its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.18) by $0.53. The biopharmaceutical company had revenue of $50.05 million for the quarter, compared to analyst estimates of $28.83 million. Acorda Therapeutics had a negative net margin of 25.94% and a negative return on equity of 6.18%. The business's revenue was down 67.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.40 EPS. View Acorda Therapeutics' Earnings History.
When is Acorda Therapeutics' next earnings date?
What price target have analysts set for ACOR?
10 Wall Street analysts have issued 1-year price targets for Acorda Therapeutics' shares. Their predictions range from $6.00 to $30.00. On average, they anticipate Acorda Therapeutics' share price to reach $13.22 in the next twelve months. This suggests a possible upside of 437.5% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.
What is the consensus analysts' recommendation for Acorda Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 2 sell ratings, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019)
- 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)
Has Acorda Therapeutics been receiving favorable news coverage?
News coverage about ACOR stock has been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Acorda Therapeutics.
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include DBV TECHNOLOGIE/S (DBVT), Replimune Group (REPL), Adverum Biotechnologies (ADVM), Cellectis (CLLS), Translate Bio (TBIO), Tcr2 Therapeutics (TCRR), Prevail Therapeutics (PRVL), Agenus (AGEN), Precision BioSciences (DTIL), Avrobio (AVRO), Harpoon Therapeutics (HARP), CASI Pharmaceuticals (CASI), Gritstone Oncology (GRTS), Cellular Biomedicine Group (CBMG) and Scholar Rock (SRRK).
What other stocks do shareholders of Acorda Therapeutics own?
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
- Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
- Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
- Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
- Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Which institutional investors are buying Acorda Therapeutics stock?
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $2.46.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $118.35 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.View Additional Information About Acorda Therapeutics.
What is Acorda Therapeutics' official website?
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
